Lv1
22 积分 2024-09-09 加入
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
4天前
已完结
An Assessment of Concerns Regarding New Regulatory Guidance for Combination Products: A Review of the Submissions Made to the FDA Regarding Their Proposed Draft New Guidance on Human Factors Studies for a Combination Product in an Abbreviated New Drug Application
1个月前
已完结
Human factors in the design of medical devices – Approaches to meeting international standards in the European Union and USA
1个月前
已完结
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
1个月前
已完结
Ozempic babies: are weight loss drugs leading to unintended pregnancies?
1个月前
已关闭
Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review
1个月前
已完结
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review
2个月前
已完结
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
2个月前
已完结
Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species
2个月前
已完结
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
3个月前
已完结
皖公网安备34019202002308
